As part of his Ph.D. in pharmacy at Université Laval, Dr. Audet-Walsh focused on the link between steroid hormones and endometrial and prostate cancers. During his work, he has demonstrated that the regulation of steroid metabolism is altered in tumor cells, notably via alterations of specific metabolic pathways. In addition, several pharmacogenomic analyses have been able to establish the link between genetic markers in steroidogenesis genes in relationship with prostate cancer progression. He then undertook a postdoctoral fellowship at McGill University, where he studied transcriptional regulation mechanisms by members of the nuclear receptor family using transcriptomic, cistromic (functional genomic) and metabolomic tools in different in vitro and in vivo models, with a particular interest in the regulation of energy metabolism. Dr. Audet-Walsh has notably demonstrated the interaction between several nuclear receptors and different cell signaling pathways in the transcriptional control of cell metabolism following various stresses. In addition, he was interested in characterizing the different waves of transcriptional regulation that involve the functional interaction between different families of transcription factors, especially in hormone-sensitive cancers.

Recently recruited at the Centre de recherche du CHU de Québec – Laval University, Dr. Audet-Walsh specializes in the study of metabolic reprogramming in hormone-sensitive cancers, by nuclear receptors. By their actions, these receptors act as master regulators of the cellular bioenergetic pathways, necessary for both the synthesis of ATP and the biosynthesis of macromolecules that are essential to cell proliferation. By using transcriptomic, cistromic and metabolomic analyzes, he wants to understand how these receptors contribute to the transcriptional regulation of different cellular metabolic pathways in physiology and disease. In addition, he also wants to understand how metabolism in turn influences hormonal signaling, since several metabolic intermediates are essential for the regulation of the epigenome. Finally, a translational research approach targeting the key elements of metabolism in pathological conditions will be used to validate its results in a context of in vitro (cells in culture) and in vivo (rodent models, human samples) models. Understanding the metabolic reprogramming associated with pathological conditions, as well as the factors that control such reprogramming, will allow the identification of new therapeutic targets in different hormone-sensitive cancers.

2705 Boulevard Laurier
Québec, QC
Canada G1V 4G2
52 entries « 6 of 6 »

Audet-Walsh E, Anderson A

Dexamethasone induction of murine CYP2B genes requires the glucocorticoid receptor

Journal Article

Drug Metab Dispos, 37 (3), 2009.

Abstract | Links:

Audet-Walsh E, Lachaud AA, Anderson A

The CYP2B2 5' flank contains a complex glucocorticoid response unit

Journal Article

Biochem Pharmacol, 76 (10), 2008.

Abstract | Links:

52 entries « 6 of 6 »
Signaler des ajouts ou des modifications

Active projects

  • Amino acid neurotransmitter reprogramming of the tumour microenvironment and metabolism in glioblastoma, from 2023-09-01 to 2025-08-31
  • Approche novatrice pour l'étude du lait maternel en contexte de diabète gestationnel : Utilisation d'un modèle d’organoïdes de la glande mammaire, from 2024-01-31 to 2025-03-31
  • Canada Research Chair in Targeting metabolic vulnerabilities for the treatment of hormone-sensitive cancers, from 2020-07-01 to 2025-06-30
  • Hydrochlorothiazide and accelerated CKD-related vascular calcification, from 2023-07-01 to 2025-06-30
  • Impact des perturbations endocriniennes sur le métabolisme de la prostate, from 2023-12-07 to 2024-12-31
  • Mitochondria bound to lipid droplets as new regulators of insulin resistance, from 2022-12-01 to 2025-11-30
  • Regulation of Cellular Energy Metabolism in Mammary Epithelial Cells, from 2019-04-01 to 2025-03-31
  • Targeting the prostate cancer metabolic program established upon loss of the KLF5 gene, from 2023-09-01 to 2025-08-31
  • Understanding mitochondrial metabolism to identify prostate cancer metabolic vulnerabilities, from 2022-10-01 to 2027-09-30
  • Unravelling the role of primary cilia in prostate cancer initiation and progression, from 2023-04-01 to 2028-03-31
  • Utilisation de modèles d'organoïdes de la glande mammaire pour l'étude du lait maternel en contexte de diabète gestationnel, from 2023-12-07 to 2024-12-31
  • What are my options? A feasibility study of a personalized primary prevention strategy for women and men at high risk of breast and prostate cancer, from 2022-01-15 to 2025-03-31

Recently finished projects

  • ABCB10 reprograms mitochondria in pro-inflammatory macrophages of obese mice, from 2022-09-21 to 2023-03-31
  • Bourse de soutien aux nouveaux détenteurs de Chaire de recherche du Canada, from 2020-07-01 to 2022-06-30
  • Caractérisation du protéome mitochondrial de la prostate, from 2022-09-21 to 2023-03-31
  • Functional interaction between the androgen and the estrogen signalling pathways in prostate cancer, from 2018-10-01 to 2023-03-31
  • Génomique fonctionnelle des récepteurs aux hormones stéroïdiennes dans le contrôle du métabolisme énergétique des cellules de cancer de la prostate, from 2019-07-01 to 2023-06-30
  • Inhibition of the AMPK metabolic program for the treatment of prostate cancer, from 2019-08-01 to 2022-07-31
  • Utilisation du dosage du citrate pour le dépistage du cancer de la prostate, from 2021-11-15 to 2022-11-14
Data provided by the Université Laval research projects registery